epigallocatechin gallate has been researched along with Adenocarcinoma of Lung in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Datta, S; Sinha, D | 1 |
| Blancafort, A; Cufí, S; Haro, D; Marrero, PF; Oliveras, G; Puig, T; Relat, J | 1 |
2 other study(ies) available for epigallocatechin gallate and Adenocarcinoma of Lung
| Article | Year |
|---|---|
Low dose epigallocatechin-3-gallate revives doxorubicin responsiveness by a redox-sensitive pathway in A549 lung adenocarcinoma cells.
Topics: A549 Cells; Adenocarcinoma of Lung; Catechin; Doxorubicin; Humans; Lung Neoplasms; Oxidation-Reduction | 2022 |
Different fatty acid metabolism effects of (-)-epigallocatechin-3-gallate and C75 in adenocarcinoma lung cancer.
Topics: 4-Butyrolactone; Adenocarcinoma; Adenocarcinoma of Lung; Analysis of Variance; Animals; Apoptosis; Carnitine O-Palmitoyltransferase; Catechin; Cell Line, Tumor; Fatty Acid Synthases; Fatty Acids; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Random Allocation; Signal Transduction; Weight Loss; Xenograft Model Antitumor Assays | 2012 |